Department of Medicine
Faculty Profiles by Division

Division of Rheumatology and Clinical Immunology

Faculty Profiles

[Return To Index page]
photo Chester V. Oddis, MD

Rheumatology

Professor of Medicine

Director, Myositis Center

Email: cvo5@pitt.edu

Phone: 412-383-8861

Contact
Office: Division of Rheumatology and Clinical Immunology
S705 BST, 3500 Terrace Street
Pittsburgh, PA 15261
 
Phone: 412-383-8861
Fax: 412-383-8864
E-mail: cvo5@pitt.edu
Administrative Assistant:
Jackie Lockhart
Address: S705A BST, 3500 Terrace Street
Pittsburgh, PA 15261
Email: lockhartj@upmc.edu
Phone: 412-383-8861
Fax: 412-383-8864
Education and Training
Education
BS, University of Pittsburgh, 1976
M.D., Pennsylvania State University College of Medicine, 1980
Training
Internship, Pennsylvania State University College of Medicine, 1884
Residency, University Hosiptal, Pennsylvania State University, 1984
Fellowship, University of Pittsburgh School of Medicine, 1987
Research Interest
Dr. Oddis has devoted his career to the investigation and treatment of inflammatory myopathy with an emphasis on epidemiology, clinical features, autoantibody associations, pathogenesis, and treatment. He has supervised and managed a clinically- and serologically-defined, longitudinal myositis registry of nearly 2,000 patients, developing a web-based Myositis Data Management System, which enables investigators to link disease activity and damage measures with clinical, laboratory and serologic data over time. Dr. Oddis was the Principal Investigator on the RIM (Rituximab in Myositis) Trial, the first multicenter clinical trial in myositis funded by the National Institutes of Health and the largest clinical trial ever completed in adult and pediatric myositis. He authored the Consensus Guidelines for the Conduct of Clinical Trials in Myositis with several colleagues. Dr. Oddis continues to coordinate myositis clinical trials with his faculty collaborators at the University of Pittsburgh including the investigation of autoimmune interstitial lung disease. Over the years, he has served on a number of multidisciplinary panels that have formulated guidelines in the assessment and management of both myositis and ILD.
Clinical Interest
My primary clinical interest is in treating idiopathic inflammatory myopathy.
Educational Interest
Dr. Oddis serves as the Associate Director of the Fellowship Training Program at the University of Pittsburgh.
Publications
For my complete bibliography, Click Here.
Selected Publications:
Traineau, H., Aggarwal, R., Monfort, J.B., Senet, P., Oddis, C.V., Chizzolini, C., Barbaud, A., Frances, C., Arnaud, L., Chasset, F. Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: A review of the literature. Journal of the American Academy of Dermatology. 2020; 82(2): 317-325.
Kass, D.J., Nouraie, M., Glassberg, M.K., Ramreddy, N., Fernandez, K., Harlow, L., Zhang, Y,, Chen, J., Kerr, G.S., Reimold, A.M., England, B.R., Mikuls, T.R., Gibson, K.F., Dellaripa, P.F., Rosas, I.O., Oddis, C.V., Ascherman, D.P. Comparative profiling of serum protein biomarkers in rheumatoid arthritis-associated interstitial lung disease and idiopathic pulmonary fibrosis. Arthritis Rheumatology. 2020; 72(3): 409-419.
Saygin, D., Oddis, C.V., Marder, G., Moghadam-Kia, S., Nandkumar, P., Neiman, N., Dzanko, S., Koontz, D., Aggarwal, R. Follow-up results of myositis patients treated with H.P. Acthar gel. Rheumatology (Oxford). Epub ahead of publication. 2020.
Eng, S.W.M., Olazagasti, J.M., Goldenberg, A., Crowson, C.S., Oddis, C.V., Niewold, T.B., Yeung, R.S.M., Reed, A.M. A clinically and biologically based subclassification of the idiopathic inflammatory myopathies using machine learning. ACR Open Rheumatology. Epub ahead of publication. 2020.
Aggarwal, R., Moghadam-Kia, S., Lacomis, D., Malik, A., Qi, Z., Koontz, D., Burlingame, R.W., Oddis, C.V. Anti-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibody in necrotizing myopathy: treatment outcomes, cancer risk, and role of autoantibody level. Scandinavian Journal of Rheumatology. 2019; 1-7.
Oddis, C.V. Myopathy for the general internist: Statins and much more. Cleveland Clinic Journal of Medicine. 2019; 86 (10): 656-664.
Moghadam-Kia, S., Charlton, D., Aggarwal, R., Oddis, C.V. Potential role of Janus kinase inhibition with tofacitinib. Rheumatology (Oxford). 2019; 58 (6): 1011-1015.
Charlton, D., Moghadam-Kia, S., Smith, K., Aggarwal, R., English, J.C., Oddis, C.V. Refractory cutaneous dermatomyositis with severe scalp pruritus responsive to apremilast. Journal of Clinical Rheumatology. 2019.
Schneider, F, Yousem, S.A., Oddis, C.V., Aggarwal, R. Pulmonary Pathologic Manifestations of Anti-Alanyl-tRNA Synthetase (Anti-PL-12)-Related Inflammatory Myopathy. Arch Pathol Lab Med. 2018; 142(2): 191-197.
Oddis, C.V., Aggarwal, R. Treatment in myositis. Nat Rev Rheumatol. 2018; 14(5): 279-289.
Sponsored Research/Activities
Title: Environmental Risk Factors for the Antisynthetase Syndrome Protocol (MYORISK)
Role: Principal Investigator
Funding Agency: Social and Scientific Systems, Inc./ National Institute of Environmental Health Sciences
Start Year: 2016
End Year: 2019
Title: Environmental Risk Factors for the Antisynthetase Syndrome Protocol (MYORISK)
Role: Principal Investigator
Funding Agency: Social and Scientific Systems, Inc.
Grant Number: N01
Start Year: 2016
End Year: 2017
Title: Autoimmunity Center of Excellence Clinical Research Program: Rituximab for Treatment of SSc-PAH (ASC01)-Mechanistic
Role: Principal Investigator
Funding Agency: University of California - San Francisco
Grant Number: UM1 AI110498
Start Year: 2016
End Year: 2017
Title: Studies of The Natural History and Pathogenesis of Autoimmune and Connective Tissue Diseases (MTA)
Role: Principal Investigator
Funding Agency: National Institute of Environmental Health Sciences
Start Year: 2015
End Year: 2020
Title: Tocilzumab in the Treatment of Refractory Polymyositis and Dermatomyositis
Role: Principal Investigator
Funding Agency: Genentech, Inc.
Start Year: 2014
End Year: 2017
Title: Collecting DNA Samples and Data for Myositis Genetics Consortium
Role: Principal Investigator
Funding Agency: National Institute of Environmental Health Sciences
Start Year: 2012
End Year: 2019
Title: Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Polymyositis (PM)
Role: Principal Investigator
Funding Agency: Genentech, Inc.
Start Year: 2006
End Year: 2017
Title: Myositis Patient Centered Tele-Research (My PACER)
Role: Co-Investigator
Funding Agency: National Institute of Arthristis, Muscoskel, & Skin Disease
Grant Number: R01 AR071659
Start Year: 2018
End Year: 2021
Title: Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease (Attack My-ILD)
Role: Co-Investigator
Funding Agency: Bristol Meyers-Squibb
Start Year: 2017
End Year: 2020
Title: Molecular Characterization of Fc Receptor Biology Index in Myositis Patients
Role: Co-Investigator
Funding Agency: Momenta Pharmaceuticals, Inc.
Grant Number: RES
Start Year: 2016
End Year: 2017
Title: Novel Outcome Measures in Adult Myositis Using a Physical Activity Monitor and the PROMIS Physical Function Assessments
Role: Co-Investigator
Funding Agency: Myositis Association
Start Year: 2015
End Year: 2017
Title: UPITT Rheumatoid Arthritis Combined Center (UPITT RACC)
Role: Co-Investigator
Funding Agency: Department of Defense
Grant Number: UH2 AR067685
Start Year: 2014
End Year: 2019